Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on profiles provided to them of emerging protease inhibitors, surveyed physicians indicate that they will prescribe Vertex/Johnson & Johnson/Mitsubishi Tanabe's telaprevir to more than 50 percent of their hepatitis C virus genotype 1-infected patients and will prescribe Schering-Plough's boceprevir to less than 30 percent of these patients. Although surveyed physicians perceive both telaprevir and boceprevir as efficacious drugs, they value (among other factors) telaprevir's shorter duration of treatment as compared to treatment duration using boceprevir.
The new Physician & Payer Forum report entitled Hepatitis C: Impact of and Receptivity to Novel Antivirals Among Payers and Prescribers finds that, among the surveyed physicians who indicate they will use both telaprevir and boceprevir for the treatment of hepatitis C virus genotype 1-infected treatment-naive patients, over 60 percent expect to start treatment for most or all of their patients with telaprevir. Surveyed physicians cite improved efficacy as the most important attribute influencing their prescribing decisions for hepatitis C virus.
"Eighty percent of the physicians we surveyed indicate that long-term efficacy is the most important attribute of novel therapies for hepatitis C virus," said Decision Resources Analyst Alexandra Makarova, M.D., Ph.D. "Nearly all surveyed physicians said that improvements in sustained virologic response in genotype 1-infected patients is the most important endpoint that will persuade them to use a novel treatment in place of currently-available therapies."
The report also finds that 40 percent of surveyed managed care organization's (MCOs) pharmacy directors indicate that they will place only one of the protease inhibitors on their formularies. Of these pharmacy directors, 10 percent expect to choose telaprevir while 30 percent say that they do not have a preference regarding telaprevir or boceprevir based on clinical data provided to them but will use cost as the basis for their selection.
Hepatitis C: Impact of and Receptivity to Novel Antivirals Among Payers and Prescribers is based on a U.S. survey of 84 gastroenterologists, 16 hepatologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.
Members of the media are welcome to attend our upcoming webinar entitled On the Verge of a Paradigm Shift in the Hepatitis C Virus Market: Physician and Payer Perceptions of Telaprevir, Boceprevir and Other Key Novel Antivirals. This webinar will be held on Thursday, September 3, 2009 at 10 a.m. U.S. Eastern Time. For more information, contact Christopher Comfort at 781-296-2597.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 firstname.lastname@example.org email@example.com
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
firstname.lastname@example.org; or Elizabeth Marshall of Decision Resources, Inc.,
Web Site: http://www.decisionresources.com/